Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Top Page
Acrivon Therapeutics, Inc.
(NASDAQ:ACRV)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▼(-1.32% Downside)
Action:ReiteratedDate:03/19/26
Score is held down primarily by weak financial performance (no revenue, sizable losses, and heavy cash burn), with additional drag from a mostly bearish longer-term technical trend. Positive recent corporate updates and cash runway provide a partial offset, but valuation metrics offer limited support given negative earnings and no dividend.
Positive Factors
Biomarker-driven precision platform
Owning a CLIA lab and a prospective OncoSignature test strengthens trial enrichment and future commercialization. Durable benefit: better patient selection raises probability of registrational success, supports targeted label claims, and creates a clinical and commercial moat versus non-biomarker competitors.
Negative Factors
No revenue; large net losses
Absence of commercial revenue and persistent large losses indicate continued reliance on capital markets. Over months this limits self-funding capacity, increases sensitivity to financing conditions, and means value is highly binary on clinical/regulatory progress rather than cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Biomarker-driven precision platform
Owning a CLIA lab and a prospective OncoSignature test strengthens trial enrichment and future commercialization. Durable benefit: better patient selection raises probability of registrational success, supports targeted label claims, and creates a clinical and commercial moat versus non-biomarker competitors.
Read all positive factors
Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$58.89M
Dividend YieldN/A
Average Volume (3M)996.44K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS Growth21.17%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding38,744,446
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$13.67Price Target Upside799.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$1.50M
Acrivon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient respon...
How the Company Makes Money
null...
Acrivon Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.36M | -1.01M | -536.00K | 0.00 | 0.00 |
| EBITDA | -82.76M | -79.55M | -59.85M | -32.29M | -16.15M |
| Net Income | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
Balance Sheet | |||||
| Total Assets | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Cash, Cash Equivalents and Short-Term Investments | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Total Debt | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Total Liabilities | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Stockholders Equity | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
Cash Flow | |||||
| Free Cash Flow | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Operating Cash Flow | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Investing Cash Flow | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Financing Cash Flow | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
Acrivon Therapeutics, Inc. Technical Analysis
Negative
1.52
Price Trends
1.64
Negative
1.96
Negative
1.75
Negative
Market Momentum
-0.07
Positive
47.54
Neutral
41.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.64, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 41.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRV.
Acrivon Therapeutics, Inc. Risk Analysis
Acrivon Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acrivon Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
ACRV
Acrivon Therapeutics, Inc.
1.52
0.01
0.66%
MNOV
Medicinova
1.44
0.20
16.13%
ALGS
Aligos Therapeutics
7.97
2.02
33.95%
GNTA
Genenta Science SpA Sponsored ADR
0.71
-2.90
-80.33%
IMMX
Immix Biopharma
8.94
7.44
496.00%
CAMP
CAMP4 Therapeutics Corporation
4.47
1.44
47.52%
Acrivon Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
Acrivon Highlights Positive ACR-368 Data and 2025 Results
Positive
Mar 19, 2026
On March 19, 2026, Acrivon Therapeutics reported fourth quarter and full-year 2025 results, highlighting progress in its registrational-intent Phase 2b trial of ACR-368 in endometrial cancer, including a 52% confirmed overall response rate in sero...
Business Operations and Strategy
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Positive
Feb 27, 2026
On February 27, 2026, Acrivon Therapeutics hosted a live, company-sponsored key opinion leader panel during the ESGO Congress in Copenhagen to discuss interim Phase 2b data from its registrational-intent ACR-368 trial in endometrial cancer. Expert...
Business Operations and StrategyProduct-Related Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
Positive
Jan 8, 2026
On January 8, 2026, Acrivon Therapeutics hosted a corporate webcast and conference call to present updated clinical data for its lead oncology programs ACR-368 and ACR-2316, alongside broader AP3 pipeline developments. The company highlighted Phas...
Business Operations and StrategyProduct-Related Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Positive
Jan 8, 2026
On January 8, 2026, Acrivon Therapeutics reported updated Phase 2b data for its CHK1/CHK2 inhibitor ACR-368 in endometrial cancer, with an interim analysis as of December 4, 2025 showing a 39% overall response rate in biomarker-positive monotherap...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.